EMPIRI is a CLIA certified laboratory and offers E-slice assay as a LDT (laboratory developed test) for clinical application. In addition, EMPIRI offers E-slice assays to our partners engaged in drug development and clinical testing.
Human cancer is composed of multiple different cell types that together form an ecosystem that is unique to each cancer patient. EMPIRI's proprietary tumor tissue slice culture is a novel 3D culture method that maintains native cell:cell and cell:matrix interactions unique to individual cancer patient's tumor. E-slice assay measures live tumor tissue treatment responses from patient tissues and experimental models. E-slice has been validated in clinical studies to accurately predict individual patient responses.
Our novel E-slice technology is also the backbone of Cal
E-slices vs. the competition
We aim to optimize precision cancer care by assisting physicians to select optimized treatment for individual patients based on empirical treatment response data.
Cal is a novel cancer diagnostic instrument in development at EMPIRI. It automates our proprietary E-slice methodology, a novel 3D culture system that retains critical cell: cell communication, extracellular matrix, and heterogeneous cell compositions that are unique and integral to each cancer ecosystem. E-slices measure dynamic responses to chemotherapies, targeted therapies, and immunotherapies. This innovative and clinically validated method can be used to measure the cytotoxic effects of individual drugs and drug combinations to optimize efficacy and reduce toxicity for each cancer patient.
Cal™ is a self-standing, automated, tissue handler that precisely and reproducibly performs EMPIRI's proprietary treatment sensitivity assays. Cal™ will accelerate and maximize clinical trials and drug discovery pipelines.
EMPIRI Cal™ is under development, if you would like to learn more or invest, click here to email us.